Neurodevelopmental Outcomes in Preschool and School Aged Children With Biliary Atresia and Their Native Liver.


Journal

Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545

Informations de publication

Date de publication:
01 2020
Historique:
pubmed: 11 9 2019
medline: 5 3 2021
entrez: 11 9 2019
Statut: ppublish

Résumé

The aim of the study was to assess neurodevelopmental outcomes among children with biliary atresia (BA) surviving with their native liver at ages 3 to 12 years and evaluate variables that associate with neurodevelopment. Participants (ages 3-12 years) in a prospective, longitudinal, multicenter study underwent neurodevelopmental testing with Weschler Preschool and Primary Scale of Intelligence, 3rd edition (WPPSI-III, ages 3-5 years) and Weschler Intelligence Scale for Children, 4th edition (WISC-IV, ages 6-12 years). Continuous scores were analyzed using Kolmogorov-Smironov tests compared with a normal distribution (mean = 100 ± 15). Effect of covariates on Full-Scale Intelligence Quotient (FSIQ) was analyzed using linear regression. Ninety-three participants completed 164 WPPSI-III (mean age 3.9) and 51 WISC-IV (mean age 6.9) tests. WPPSI-III FSIQ (104 ± 14, P < 0.02), Verbal IQ (106 ± 14, P < 0.001), and General Language Composite (107 ± 16, P < 0.001) distributions were shifted higher compared with test norms. WISC-IV FSIQ (105 ± 12, P < 0.01), Perceptual Reasoning Index (107 ± 12, P < 0.01), and Processing Speed Index (105 ± 10, P < 0.02) also shifted upwards. In univariate and multivariable analysis, parent education (P < 0.01) was a significant predictor of FSIQ on WPPSI-III and positively associated with WISC-IV FSIQ. Male sex and higher total bilirubin and gamma glutamyl transferase (GGT) predicted lower WPPSI-III FSIQ. Portal hypertension was predictive of lower WISC-IV FSIQ. This cohort of children with BA and native liver did not demonstrate higher prevalence of neurodevelopmental delays. Markers of advanced liver disease (higher total bilirubin and GGT for age ≤5 years; portal hypertension for age ≥6) correlate with lower FSIQ and may identify a vulnerable subset of patients who would benefit from intervention.

Identifiants

pubmed: 31503218
doi: 10.1097/MPG.0000000000002489
pmc: PMC6934908
mid: NIHMS1538645
pii: 00005176-202001000-00016
doi:

Substances chimiques

gamma-Glutamyltransferase EC 2.3.2.2
Bilirubin RFM9X3LJ49

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-86

Subventions

Organisme : NIDDK NIH HHS
ID : U01 DK062481
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062470
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001857
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062436
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001108
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062452
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062466
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK084575
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK084536
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062456
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000077
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103149
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK062456
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000130
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103140
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001872
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001878
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK084538
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062453
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062503
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002535
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103135
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000454
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025014
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK120531
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001855
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062445
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000423
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062500
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK062497
Pays : United States

Références

Harpavat S, Garcia-Prats JA, Shneider BL. Newborn bilirubin screening for biliary atresia. N Engl J Med 2016; 375:605–606.
Wang KS. Section on Surgery; Committee on Fetus and Newborn; Childhood Liver Disease Research Network. Newborn Screening for Biliary Atresia. Pediatrics 2015; 136:e1663–e1669.
Bezerra JA, Wells RG, Mack CL, et al. Biliary Atresia: Clinical and Research Challenges for the 21st Century. Hepatology 2018; doi: 10.1002/hep.29905. [Epub ahead of print].
doi: 10.1002/hep.29905.
Sanchez-Valle A, Kassira N, Varela VC, et al. Biliary atresia: epidemiology, genetics, clinical update, and public health perspective. Adv Pediatr 2017; 64:285–305.
Chin SE, Shepherd RW, Cleghorn GJ, et al. Survival, growth and quality of life in children after orthotopic liver transplantation: a 5 year experience. J Paediatr Child Health 1991; 27:380–385.
Moser JJ, Veale PM, McAllister DL, et al. A systematic review and quantitative analysis of neurocognitive outcomes in children with four chronic illnesses. Paediatr Anaesth 2013; 23:1084–1096.
Stewart SM, Hiltebeitel C, Nici J, et al. Neuropsychological outcome of pediatric liver transplantation. Pediatrics 1991; 87:367–376.
Stewart SM, Uauy R, Waller DA, et al. Mental and motor development, social competence, and growth one year after successful pediatric liver transplantation. J Pediatr 1989; 114 (4 Pt 1):574–581.
Rodijk LH, den Heijer AE, Hulscher JBF, et al. Neurodevelopmental outcomes in children with liver diseases: a systematic review. J Pediatr Gastroenterol Nutr 2018; 67:157–168.
Johnson RJ, Warady BA. Long-term neurocognitive outcomes of patients with end-stage renal disease during infancy. Pediatr Nephrol 2013; 28:1283–1291.
Caudle SE, Katzenstein JM, Karpen SJ, et al. Language and motor skills are impaired in infants with biliary atresia before transplantation. J Pediatr 2010; 156:936.e1–940.e1.
Wayman KI, Cox KL, Esquivel CO. Neurodevelopmental outcome of young children with extrahepatic biliary atresia 1 year after liver transplantation. J Pediatr 1997; 131:894–898.
Sundaram SS, Mack CL, Feldman AG, et al. Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care. Liver Transpl 2017; 23:96–109.
Lind RC, de Vries W, Keyzer CM, et al. Health status and quality of life in adult biliary atresia patients surviving with their native livers. Eur J Pediatr Surg 2015; 25:e2.
Ng VL, Haber BH, Magee JC, et al. Medical status of 219 children with biliary atresia surviving long-term with their native livers: results from a North American multicenter consortium. J Pediatr 2014; 165:539.e2–546.e2.
Walton MK, Powers JH 3rd, Hobart J, et al. International Society for Pharmacoeconomics and Outcomes Research Task Force for Clinical Outcomes Assessment. Clinical outcome assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force. Value Health 2015; 18:741–752.
Ng VL, Sorensen LG, Alonso EM, et al. Neurodevelopmental outcome of young children with biliary atresia and native liver: results from the ChiLDReN Study. J Pediatr 2018; 196:139.e3–147.e3.
Bezerra JA, Spino C, Magee JC, et al. Childhood Liver Disease Research and Education Network (ChiLDREN). Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial. JAMA 2014; 311:1750–1759.
Shneider BL, Abel B, Haber B, et al. Portal hypertension in children and young adults with biliary atresia. J Pediatr Gastroenterol Nutr 2012; 55:567–573.
Bass LM YW, Hawthorne K, Leung DH, et al. for the ChiLDReN Network. Natural history and risk factors for variceal hemorrhage in biliary atresia: results of a prospective multi-center longitudinal analysis. Digestive Diseases Week (DDW), Washington DC, June 2–5, 2018.
Bass LM, Shneider BL, Henn L, et al. Childhood Liver Disease Research Network. Clinically evident portal hypertension: an operational research definition for future investigations in the pediatric population. J Pediatr Gastroenterol Nutr 2019; 68:763–767.
A SAS Program for the 2000 CDC Growth Charts (ages 0 to <20 years) Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion 2016. Available at: https://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm. Accessed 1 November 2015.
Raghuanthan TE, Solenberger PW, Berglund P, Van Hoewyk J. IVEware: Imputation and Variance Estimation Software. Version 0.3. The Regents of the University of Michigan, 2016 1-81.
Chen Q, Wang S. Variable selection for multiply-imputed data with application to dioxin exposure study. Stat Med 2013; 32:3646–3659.
Harpavat S, Lupo PJ, Liwanag L, et al. Factors influencing time-to-diagnosis of biliary atresia. J Pediatr Gastroenterol Nutr 2018; 66:850–856.
Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 2006; 24:1305–1309.
Mannson JSK, Serenius F, Aden U, et al. Agreement between Bayley-III measurements and WISC-IV measurements in typically developing children. J Psychoeduc Assess 2018; 37:603–616.
Anderson V, Spencer-Smith M, Wood A. Do children really recover better? Neurobehavioural plasticity after early brain insult. Brain 2011; 134 (Pt 8):2197–2221.
Caudle SE, Katzenstein JM, Karpen S, et al. Developmental assessment of infants with biliary atresia: differences between boys and girls. J Pediatr Gastroenterol Nutr 2012; 55:384–389.
Gold A, Rogers A, Cruchley E, et al. Assessment of school readiness in chronic cholestatic liver disease: a pilot study examining children with and without liver transplantation. Can J Gastroenterol Hepatol 2017; 2017:9873945.
Adeback P, Nemeth A, Fischler B. Cognitive and emotional outcome after pediatric liver transplantation. Pediatr Transplant 2003; 7:385–389.
Alonso EM, Sorensen LG. Cognitive development following pediatric solid organ transplantation. Curr Opin Organ Transplant 2009; 14:522–525.
Gilmour S, Adkins R, Liddell GA, et al. Assessment of psychoeducational outcomes after pediatric liver transplant. Am J Transplant 2009; 9:294–300.
Gritti A, Di Sarno AM, Comito M, et al. Psychological impact of liver transplantation on children's inner worlds. Pediatr Transplant 2001; 5:37–43.
Kaller T, Langguth N, Petermann F, et al. Cognitive performance in pediatric liver transplant recipients. Am J Transplant 2013; 13:2956–2965.
Krull K, Fuchs C, Yurk H, et al. Neurocognitive outcome in pediatric liver transplant recipients. Pediatr Transplant 2003; 7:111–118.
Robertson CM, Dinu IA, Joffe AR, et al. Western Canadian Therapies Follow-up Group. Neurocognitive outcomes at kindergarten entry after liver transplantation at <3 yr of age. Pediatr Transplant 2013; 17:621–630.
Sorensen LG, Neighbors K, Martz K, et al. Studies of Pediatric Liver Transplantation (SPLIT) and Functional Outcomes Group (FOG). Cognitive and academic outcomes after pediatric liver transplantation: Functional Outcomes Group (FOG) results. Am J Transplant 2011; 11:303–311.
Sorensen LG, Neighbors K, Martz K, et al. Longitudinal study of cognitive and academic outcomes after pediatric liver transplantation. J Pediatr 2014; 165:65.e2–72.e2.
Trahan LH, Stuebing KK, Fletcher JM, et al. The Flynn effect: a meta-analysis. Psychol Bull 2014; 140:1332–1360.
Sundaram SS, Alonso EM, Haber B, et al. Health related quality of life in patients with biliary atresia surviving with their native liver. J Pediatr 2013; 163:1052–1057.e2.

Auteurs

James E Squires (JE)

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Vicky Lee Ng (VL)

Division of GI, Hepatology and Nutrition, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.

Kieran Hawthorne (K)

Arbor Research Collaborative for Health.

Lisa L Henn (LL)

Arbor Research Collaborative for Health.

Lisa G Sorensen (LG)

Department of Pediatrics, Michigan Medicine, Ann Arbor, MI.

Emily M Fredericks (EM)

Department of Pediatrics, Michigan Medicine, Ann Arbor, MI.

Estella M Alonso (EM)

Ann and Robert Lurie Children's Hospital, Chicago, IL.

Karen F Murray (KF)

Division of GI and Hepatology, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA.

Kathleen M Loomes (KM)

Division of GI, Hepatology and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA.

Saul J Karpen (SJ)

Division of GI, Hepatology and Nutrition, Emory University School of Medicine, Atlanta, GA.

Laurel A Cavallo (LA)

Division of GI, Hepatology and Nutrition, Baylor College of Medicine, Houston, TX.

Jean P Molleston (JP)

Division of GI, Hepatology and Nutrition, Indiana University, Riley Hospital for Children, Indianapolis, IN.

Jorge A Bezerra (JA)

Division of GI, Hepatology and Nutrition, Cincinnati Children's Medical Center, Cincinnati, OH.

Philip Rosenthal (P)

Division of GI, Hepatology and Nutrition, UCSF, San Francisco, CA.

Robert H Squires (RH)

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Kasper S Wang (KS)

Department of Pediatric Surgery, Children's Hospital Los Angeles, CA.

Kathleen B Schwarz (KB)

Johns Hopkins School of Medicine, Baltimore, MD.

Ronen Arnon (R)

Division of GI, Hepatology and Nutrition, Mt. Sinai Medical Center, New York, NY.

John C Magee (JC)

Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI.

Ronald J Sokol (RJ)

Section of Pediatric GI, Hepatology and Nutrition, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, CO.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH